ELECTROCORE, INC. (NASDAQ: ECOR) - PLANET MICROCAP TORONTO - ELECTROCORE INC

Explicit Guidance:

• Adjusted EBITDA: Target to achieve adjusted EBITDA positivity in the back half of 2027.
• Revenue Run Rate: Revenue run rate is approximately $40 million as of mid-2026 (based on $19M revenue in H1 2025 and projected full-year 2025 revenue of ~$32M).
• Sales & Marketing Efficiency: Goal to reduce sales and marketing expenses as a percentage of revenue from ~60% (historical) to 40–50% (industry norm) by achieving operational scale.
• Debt Amortization: Debt amortization on existing ~$7.5 million in debt is scheduled to begin in March 2027.

Business-Segment Outlook:

• VA Expansion (Headache & Fibromyalgia): Plans to penetrate the remaining 70% of VA headache accounts (currently serving ~3% of the 600,000 patient population) and expand Quell Fibromyalgia sales (currently in ~30% of accounts) over the next two years.
• New Indications (CIPN): Filing a 510(k) for Chemotherapy-Induced Peripheral Neuropathy (CIPN) with "breakthrough designation" status; the market affects ~50% of chemotherapy patients (700,000 annually in the US, ~15,000–20,000 annually within the VA).
• Consumer Health (TruVega): Strategic pivot to prioritize profitability over triple-digit growth in the direct-to-consumer segment to support EBITDA targets.
• General Wellness (TACSTIM): Continued B2B expansion of the white-labeled TACSTIM device for active duty military (cognitive enhancement/performance) and direct-to-consumer sales.
• Commercial Diversification: Leveraging the late 2025 Kaiser Permanente formulary/contract win (12.5 million lives) to reduce reliance on the VA (9.5 million covered lives).

Market and Competitive Outlook:

• VA Market Dynamics: Recognized as a fragmented marketplace of 170 unique customers (VA Medical Centers) and 1,300 prescription-writing locations; significant "first-mover" advantage expected due to the lack of non-opioid alternatives for fibromyalgia and the systemic nature of vagus nerve stimulation vs. "sniper shot" pharmaceuticals.
• Competitive Landscape: Quell is positioned as the only FDA-approved product specifically for fibromyalgia; CIPN indication would create a proprietary product with no current direct competitors in the device/pharma space for that specific indication.
• Indication Expansion: Potential for multiple indications beyond headaches via ongoing research in PTSD, mild traumatic brain injury, gastroparesis, and stroke, leveraging a portfolio of ~250 patents and 30+ investigator-initiated trials.

Macro / Industry Outlook:

• Federal Marketplace Growth: Anticipated expansion into Federal Workers' Comp, TRICARE, and Medical Treatment Facilities beyond the VA, driven by new commercial leadership with 10–15 years of federal sales experience.
• Regulatory Trajectory: Management notes a shift from "de novo" to "510(k)" filing paths for new indications (CIPN) based on FDA feedback, streamlining the regulatory timeline.
• Cap Table Stability: No external dilution threats (no ratchets, anti-dilutes, or black shoals warrants) and low reliance on public equity capital markets, as the company is not currently seeking capital.

Strategic Initiatives:

• Leadership Change: Implementation of a new Co-CEO (Mike Fox, former federal device sales expert) and COE structure in April 2026 to drive commercial expansion.
• Acquisition Integration: Full commercial integration of Neurometrics (acquired May 2025), growing Quell Fibromyalgia revenue from $50k/month at acquisition to ~$1.3M in the most recent quarter.
• Product Development: Acceleration of new product features and indications, with the CIPN filing noted as the first new indication filing in five years.
• Capital Allocation: Focus on maintaining a "clean cap table" with insider/bond warrant holdings to protect shareholder equity.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Dependence on FDA approval timelines for the new CIPN indication and potential delays in expanding indications (e.g., PTSD).
• Commercial Execution Risk: Success in diversifying revenue relies heavily on the new leadership's ability to penetrate non-VA federal and commercial markets (Kaiser, TRICARE).
• Product Adoption Pace: The speed of adoption in the fragmented VA system (1,300 locations) is a variable; management acknowledges the need to "show up" physically to sell.
• Margin Pressure: Consumer segment margins are lower than the medical device segment; aggressive growth in this area could threaten EBITDA targets if not carefully managed.

Management Tone on the Future:

• Confidence Level: High confidence in the scalability of the business post-transition, citing a 50% compounded annual revenue growth over the last five years and a shift from R&D to a scalable commercial engine.
• Valuation Perspective: Management believes the stock is undervalued, trading at 1.9–2.0x forward revenue compared to a 10-year industry mean of ~4.5x, and cites an 71–182% stock appreciation since December 2025 as validation of market recognition.
• Strategic Pivot: Tone shifts from "turnaround mode" to "inflection point," emphasizing that the company is no longer a "single product, single customer" entity but a platform with multiple shots on net.

Miscellaneous:

• Stock Performance: Stock price appreciated ~71–72% since December 2025, with a peak improvement of ~182% year-to-date at the time of the presentation.
• Patent Protection: Core IP covers cervical non-invasive vagal nerve stimulation (leveraging 80–90% of vagal fibers in the neck) and mobile app control, creating barriers against auricular-only competitors.